Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2014 1
2019 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, Diep L, Jang A, Nguyen MT, Lapuyade N, Singson V, Villanueva R, Paidhungat M, Liu S, Rangan V, Vasiljeva O, West JW, Richardson JH, Irving B, Daniel D, Belvin M, Kavanaugh WM. Assi HH, et al. Cancer Immunol Res. 2021 Dec;9(12):1451-1464. doi: 10.1158/2326-6066.CIR-21-0031. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635485
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.
Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG. Assi HH, et al. J Pharmacol Exp Ther. 2014 Jun;349(3):458-69. doi: 10.1124/jpet.114.214619. Epub 2014 Apr 2. J Pharmacol Exp Ther. 2014. PMID: 24696041 Free PMC article.